National Academies Press: OpenBook
« Previous: 9 Market Obstacles and Creating Incentives
Suggested Citation:"Appendix A: Acknowledgments." Institute of Medicine. 1995. The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington, DC: The National Academies Press. doi: 10.17226/4906.
×
Page 201
Suggested Citation:"Appendix A: Acknowledgments." Institute of Medicine. 1995. The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington, DC: The National Academies Press. doi: 10.17226/4906.
×
Page 202
Suggested Citation:"Appendix A: Acknowledgments." Institute of Medicine. 1995. The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington, DC: The National Academies Press. doi: 10.17226/4906.
×
Page 203
Suggested Citation:"Appendix A: Acknowledgments." Institute of Medicine. 1995. The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington, DC: The National Academies Press. doi: 10.17226/4906.
×
Page 204
Suggested Citation:"Appendix A: Acknowledgments." Institute of Medicine. 1995. The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington, DC: The National Academies Press. doi: 10.17226/4906.
×
Page 205
Suggested Citation:"Appendix A: Acknowledgments." Institute of Medicine. 1995. The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington, DC: The National Academies Press. doi: 10.17226/4906.
×
Page 206

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Appendix A Acknowledgments The committee would like to thank the following persons who shared their expertise. John Abbott National Institute on Drug Abuse John Ambre American Medical Association Robert Angarola Hyman, Phelps and McNamara Douglas Anglin University of California Bruce Artim National Institutes of Health Dennis Baker Texas Department of Health John F. Beary Pharmaceutical Research and Manufacturers of America 201 Martin Becker, Esq. New York, NY Walter Bell National Institute of Neurological Disorders and Stroke Leslie Benet University of California Shawn Bentley Senate Judiciary Committee Alex Bradford BioDevelopment Corporation Peter Bridge National Institute on Drug Abuse Bruce Burlington Food and Drug Administration

202 DEVELOPMENT OF MEDICATIONS William Butynski National Association of State Alcohol and Drug Abuse Directors Robert Callahan American Society of Addiction Medicine, Inc. Neal Castagnoli Virginia State University John Coleman Drug Enforcement Administration Shirley Coletti McCormick Research Center Joseph Collins Department of Veterans Affairs Tim Condon National Institute on Drug Abuse Gary Coody Texas Department of Health James Cooper National Institute on Drug Abuse Addle Corradi New York State Office of Alcoholism and Substance Abuse Services Paul Coulis National Institute on Drug Abuse Lee Cummings National Institute on Drug Abuse Albert Derivan Wyeth-Ayerst Research George DeVaux BioDevelopment Corporation Kay Dickersin University of Maryland School of Medicine Carl W. Dieffenbach National Institute of Allergy and Infectious Diseases Herman Diesenhaus Substance Abuse and Mental Health Services Administration Christopher Doherty Fox, Bennett and Turner Jack Durell Treatment Research Institute Robert Eaton Pharmaceutical Manufacturers Association Barbara Espey Massachusetts Department of Public Health Susan Everingham RAND Rachel Feldman Lewin-VHI, Inc. Marian Fischman Columbia University

APPENDIX A Michael Friedman National Cancer Institute Judy Galloway Substance Abuse and Mental Health Services Administration Fred Garcia Office of National Drug Control Policy Ronald Garity Medco Behavioral Care Ann Geller American Society of Addiction Medicine Dee Gillespie DuPont Pharmaceutical Thomas Gitchel Drug Enforcement Administration Richard Golden Department of Alcohol and Drug Programs, State of California Avram Goldstein Stanford University Frederick K. Goodwin National Institute of Mental Health Eric Goplerud Substance Abuse and Mental Health Services Administration 203 John Gregrich Office of National Drug Control Policy Steve Grossman Hill and Knowlton Charles Grudzinskas National Institute on Drug Abuse Gene Haislip Drug Enforcement Administration Louis Harris Medical College of Virginia Christine Hartel National Institute on Drug Abuse Henrick Harwood Lewin-VHI, Inc. Richard Hawks National Institute on Drug Abuse Rebecca Henderson Massachusetts Institute of Technology Carol Hubner National Institute on Drug Abuse James Isbister Pharmavene, Inc. David Joranson University of Wisconsin Medical School

204 DEVELOPMENT OF MEDICATIONS Ruth Kahn Health Resources and Services Administration Janice F. Kauffman Substance Abuse Treatment Services Tom Kellenberger Medco Containment Services Richard Kilburg Johns Hopkins University Richard Kitz Massachusetts General Hospital Delbert Konnor American Managed Care Pharmacy Association Thomas Kosten Yale University Harvey Kupferberg National Institute of Neurological Disorders and Stroke Laurie Kurtzman New York State Office of Alcoholism and Drug Abuse Services Irwin Lerner Hoffmann-La Roche Robert Levy Wyeth-Ayerst Research David Lewis Brown University Robert Lubran Substance Abuse and Mental Health Services Administration Karen Marquis Wyeth-Ayerst David W. Martin, Jr. Du Pont Merck Pharmaceutical Company David McCann National Institute on Drug Abuse Mary Elizabeth McCaul Johns Hopkins University Hospital Howard McClain Drug Enforcement Administration Catherine McCormack Generic Pharmaceutical Industry Association Thomas McLellan Penn-VA Center for Studies of Addiction Daniel Melnick Substance Abuse and Mental Health Services Administration Richard Merrill University of Virginia School of Law Harry Meyer American Cyanamid Company

APPENDIX A Corrine Moody Food and Drug Administration Ed Morgan Substance Abuse and Mental Health Services Administration Dave Neuenschwander Mallinckrodt Chemical, Inc. Stuart Nightingale Food and Drug Administration Stanley Novick National Alliance of Methadone Advocates John A. Gates Vanderbilt University Mark Parrino American Methadone Treatment Association Nancy Payte Drug Dependence Associates Thomas Payte Drug Dependence Associates Dana Peale Cure is Not Worse Chris Putala Senate Judiciary Committee Scott Reines Merck Research Laboratories Nicholas P. Reuter Food and Drug Administration 205 Peter Riddell RAND Barbara Roberts Office of National Drug Control Policy Sheri L. Samotin The Wilkerson Group, Inc. Charles Sanders Glaxo Inc. Frank Sapienza Drug Enforcement Administration Alan Sartorelli Yale University School of Medicine Clifford Scharke National Institutes of Health Saul Schepartz National Cancer Institute David Schieser California Research Advisory Panel Sam Schildhaus Office of National Drug Control Policy Ian Shaffer Value Behavioral Health Dale Shoemaker National Cancer Institute

206 DEVELOPMENT OF MEDICATIONS Robert Sisko International Coalition for Addict Self Help Eve Slater Merck Research Laboratory Michael Smith Lincoln Hospital, New York Marvin Snyder National Institute on Drug Abuse Solomon Snyder Johns Hopkins University Steve Tabscot Texas Methadone Provider Group Robert Temple Food and Drug Administration John Thomas BioDevelopment Corporation Richard Thoreson Substance Abuse and Mental Health Services Administration Alan Trachtenberg National Institute on Drug Abuse Frank Vocci National Institute on Drug Abuse Jeane Van Lear Biotechnology Industry Organization William Vodra Arnold and Porter Ellen Weber Legal Action Center Bonnie Wilford George Washington University Curtis Wright Food and Drug Administration Paul Wohlford Substance Abuse and Mental Health Services Administration Thomas Wyatt National Association of State Controlled Substance Authorities Michael Young Proctor & Gamble

Next: Appendix B: Organization and Mission Statements of NIDA's Medications Development Division and Its Branches »
The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector Get This Book
×
Buy Paperback | $54.00 Buy Ebook | $43.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Pharmacotherapy, as a means of treating drug addiction in combination with other treatment modalities, has received too little attention from the research community, the pharmaceutical industry, public health officials, and the federal government. Medications to combat drug addiction could have an enormous impact on the medical consequences and socioeconomic problems associated with drug abuse, both for drug-dependent individuals and for American society as a whole. This book examines the current environment for and obstacles to the development of anti-addiction medications, specifically those for treating opiate and cocaine addictions, and proposes incentives for the pharmaceutical industry that would help overcome those obstacles and accelerate the development of anti-addiction medications.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!